Aflatoxin B1-induced immortalization of cultured skin fibroblasts from a patient with Li-Fraumeni syndrome.
To examine the mechanisms of immortalization in human cells, normal human diploid fibroblasts (WHE-7) and skin fibroblasts from a patient with Li-Fraumeni syndrome (MDAH 087) and a mutant p53 allele were treated with aflatoxin B1 (AFB1). Exogenous metabolic activation of AFB1 with rat liver post-mitochondrial supernatant (PMS) was used and the optimal treatment conditions needed were determined by the inducibility of unscheduled DNA synthesis. The same degree of cytotoxicity was observed with MDAH 087 cells and normal WHE-7 cells treated with AFB1 at 0.1, 0.3 or 1 microgram/ml for 2 h with a 2% PMS mixture. All WHE-7 cell cultures (AFB1-treated and controls) failed to escape from senescence, whereas three out of nine AFB1-treated cultures of MDAH 087 cells escaped senescence. MDAH 087 cells treated with 0.1 microgram/ml of AFB1 two or three times initially decreased in growth approximately 40 days [10 population doublings (PD)] after the first treatment. However, the cells recovered with faster growth rates after approximately 100 additional days and grew continuously. Both cultures were immortal, defined as continuous growth for over 300 PD. Cells treated once with 0.3 microgram/ml of AFB1 also escaped senescence, although they had about a 230 day time lag before restoration of cell growth. The three AFB1-treated cell lines exhibited altered morphologies, chromosome aberrations (numerical and structural aberrations) and loss of the wild-type p53 allele. Although immortal, the cells were non-tumorigenic in nude mice. Spontaneous immortalization of untreated MDAH 087 was not observed in this study. The results indicate that AFB1 treatment of cells from a Li-Fraumeni patient, but not cells from normal individuals, can induce immortalization. This model may be useful for studying mechanisms of chemically induced immortalization.
Department of Pharmacology, Nippon Dental University, School of Dentistry at Tokyo, Japan.
T
T
Tsutsui
T
T
Fujino
S
S
Kodama
M A
MA
Tainsky
J
J
Boyd
J C
JC
Barrett
D000328:Adult; D016604:Aflatoxin B1 / Q000493:pharmacokinetics / Q000633:toxicity*; D001711:Biotransformation; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D016922:Cellular Senescence / Q000187:drug effects; D004247:DNA / Q000032:analysis / Q000096:biosynthesis / Q000235:genetics; D016172:DNA Fingerprinting; D005347:Fibroblasts / Q000166:cytology* / Q000187:drug effects* / Q000502:physiology; D016158:Genes, p53 / Q000187:drug effects; D006801:Humans; D007621:Karyotyping; D016864:Li-Fraumeni Syndrome / Q000473:pathology*; D008297:Male; D008769:Methylnitronitrosoguanidine / Q000633:toxicity; D009154:Mutation; D012867:Skin / Q000166:cytology* / Q000187:drug effects*; D012879:Skin Physiological Phenomena
D008769:Methylnitronitrosoguanidine; D004247:DNA; D016604:Aflatoxin B1